Treatment of osteoporosis
AssigneeMayo Foundation for Medical Education and Research
InventorsSundeep Khosla, Cheryl A. Conover, Francis J. Ballard, Peter M. Tapley
Life of this patent
Estimating the term…
Abstract
A substantially pure complex including IGFIIE polypeptide and IGFBP2 polypeptide is described. Methods for treating an osteoporosis patient and targeting a compound to the skeletal extracellular matrix of a patient are also described.
Claims32
A composition comprising a substantially pure complex and a physiologically acceptable buffer, said complex comprising an IGFIIE polypeptide and an IGFBP2 polypeptide, wherein said IGFIIE polypeptide is a fragment of full-length IGFIIE polypeptide, said fragment having the biological activity of the full-length IGFIIE polypeptide, and wherein said composition is substantially free of uncomplexed IGFIIE polypeptide.
A method of treating an osteoporosis patient comprising administering an amount of a composition comprising an IGFIIE polypeptide and an IGFBP2 polypeptide effective to treat said osteoporosis patient wherein said IGFIIE polypeptide is a fragment of full-length IGFIIE polypeptide, said fragment having the biological activity of the full-length IGFIIE polypeptide.
A method of targeting a compound to skeletal extracellular matrix of a patient comprising administering a composition to said patient, wherein said composition comprises a complex of an IGFIIE polypeptide, an IGFBP2 polypeptide, and said compound, wherein said IGFIIE polypeptide is a fragment of full-length IGFIIE polypeptide, said fragment having the biological activity of the full-length IGFIIE polypeptide.
A pharmaceutical composition comprising an IGFIIE polypeptide and an IGFBP2 polypeptide in amounts effective to increase bone mass in a mammal, and a physiologically acceptable buffer, wherein said IGFIIE polypeptide is a fragment of full-length IGFIIE polypeptide and is unlabeled, said fragment having the biological activity of the full-length IGFIIE polypeptide.
An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein the pharmaceutical agent comprises amounts of an IGFIIE polypeptide and an IGFBP2 polypeptide therapeutically effective for increasing bone mass, wherein said IGFIIE polypeptide is a fragment of full-length IGFIIE polypeptide, said fragment having the biological activity of the full-length IGFIIE polypeptide, and wherein said packaging material comprises a label or package insert indicating that said pharmaceutical agent can be used for increasing bone mass or treating osteoporosis.
A method for increasing bone mass in a patient comprising administering an amount of an IGFIIE polypeptide and an amount of an IGFBP2 polypeptide effective to increase bone mass in said patient, wherein said IGFIIE polypeptide is a fragment of full-length IGFIIE polypeptide, said fragment having the biological activity of full-length IGFIIE polypeptide.
A composition comprising a substantially pure complex and a physiologically acceptable buffer, said complex comprising an IGFIIE polypeptide and an IGFBP2 polypeptide, wherein said IGFIIE polypeptide is a fragment of full-length IGFIIE polypeptide and is unlabeled, said fragment having the biological activity of the full-length IGFIIE polypeptide.
Dependencies are inferred from the claim text.